About Cancer: Biology, Classification & Research
A comprehensive clinical introduction to cancer pathogenesis, cellular hallmarks, major classifications, oncogenomics, and therapeutic evolution.
What is Cancer?
Cancer is a complex family of diseases characterized by unregulated cellular proliferation, evasion of programmed cell death (apoptosis), and the capacity of malignant cells to invade adjacent anatomical structures and metastasize to distant organs via vascular or lymphatic channels.
In healthy physiological homeostasis, cellular replication and turnover are strictly regulated. Cellular transformation into malignancy arises when sequential acquired or inherited somatic mutations alter critical regulatory pathways governing genomic stability, DNA repair, and cell cycle checkpoints.
The Biological Hallmarks of Malignancy
During oncogenesis, neoplastic cells acquire distinct biological capabilities:
- Self-Sufficiency in Growth Signals: Sustained proliferative signaling through mutated or hyperactive oncogenes.
- Insensitivity to Antigrowth Signals: Inactivation of tumor suppressor genes such as TP53, RB1, and PTEN.
- Evasion of Programmed Apoptosis: Resistance to cell death mechanisms via overexpression of anti-apoptotic proteins (e.g., BCL-2).
- Limitless Replicative Potential: Telomerase reactivation enabling continuous cellular immortality.
- Sustained Angiogenesis: Secretion of pro-angiogenic factors like VEGF to form new tumor vasculature.
- Tissue Invasion and Metastasis: Loss of cell-cell adhesion (E-cadherin downregulation) and extracellular matrix degradation.
Primary Histological Classifications
| Classification |
Tissue of Origin |
Clinical Examples |
| Carcinoma |
Epithelial cells lining internal organs and external body surfaces |
Adenocarcinoma of breast, lung, prostate, colon; Squamous cell carcinoma |
| Sarcoma |
Mesenchymal connective tissues (bone, cartilage, muscle, fat) |
Osteosarcoma, Leiomyosarcoma, Liposarcoma, Ewing sarcoma |
| Leukemia |
Bone marrow blood-forming hematological stem cells |
Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL) |
| Lymphoma |
Lymphatic system nodes and immune lymphocytes |
Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL) |
| Central Nervous System |
Brain and spinal cord glial cells and meninges |
Glioblastoma, Astrocytoma, Meningioma |
Oncogenomics and Precision Medicine
Next-Generation Sequencing (NGS) has shifted modern oncology from organ-based treatment paradigms toward molecularly guided precision therapeutics. Identifying actionable driver mutations allows clinicians to select targeted therapies designed to inhibit the exact molecular aberrations fueling tumor growth:
- Targeted Inhibitors: Small-molecule tyrosine kinase inhibitors (e.g., EGFR, ALK, ROS1, BRAF inhibitors).
- Immune Checkpoint Blockade: Monoclonal antibodies (anti-PD-1, anti-PD-L1, anti-CTLA-4) that reactivate cytotoxic T-lymphocytes against tumor antigens.
- Liquid Biopsies: Circulating tumor DNA (ctDNA) assays that enable non-invasive molecular profiling, early recurrence monitoring, and minimal residual disease (MRD) detection.
Multidisciplinary Cancer Management
Optimal outcomes require coordination across specialized oncology disciplines:
- Surgical Oncology: Accurate tumor staging, primary resection with clear margins, and reconstructive surgery.
- Medical Oncology: Systemic chemotherapies, targeted therapies, immunotherapies, and endocrine regimens.
- Radiation Oncology: Stereotactic body radiation therapy (SBRT), intensity-modulated radiotherapy (IMRT), and proton therapy.
- Palliative and Supportive Care: Proactive symptom control, nutritional optimization, psychological support, and pain management throughout all phases of treatment.
Rapid advancements in genomic profiling and immunotherapy continue to expand effective treatment options and improve long-term survival across nearly every tumor type.
